Sodium o-iodoppyrate, 123-I (Sodium o-iodohippurate, isotope 123-I)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceSodium iodopyrupate, 123-ISodium iodopyrupate, 123-I
Dosage form: & nbspsolution for intravenous administration
Composition:

Active substance:

Yoda-123 not less than 100 MBq

Excipients:

Sodium o-iodoppurate 8.0 mg

Sodium chloride 6.75 mg

Phosphorus in the form of sodium dihydrogen phosphate dihydrate 0.2 mg

Water for Injection up to 1 ml

Description:

Colorless transparent liquid.

Pharmacotherapeutic group:Radiopharmaceutical diagnostic tool
ATX: & nbsp

V.09.C.X   Other radiopharmaceuticals for the detection of kidney diseases

Pharmacodynamics:

Sodium o-iodoppurate 123I - radiopharmaceutical diagnostic preparation, is an aqueous solution of the sodium salt of ortho-iodoppyrope acid labeled with iodine-123, the radiochemical purity of the preparation is 97%. Volumetric activity of at least 100 MBq / ml at the date and time of preparation. Iodine-123 decays with a half-life of 13.2 hours and has the most intense component of gamma radiation with an energy of 159.0 keV (83.4%).The drug is sterile and pyrogen-free, pH 5-8.

Pharmacology (diagnostic properties)

The distribution of the drug in the body allows the use of sodium o-iodoppyrate, 123I dFor radioisotope studies of the kidneys and urinary tract by renography and dynamic scintigraphy.

Pharmacokinetics:Sodium o-iodoppurate 123I after intravenous injection quickly leaves the vascular bed, secreted by the epithelium of the renal tubules into the urine. Half-life of the indicator from the blood is 6-8 minutes. The maximum accumulation of the drug in the kidneys is normally recorded for 2-3 minutes and is about 20%. For 1 hour, about 90% of the drug is excreted.
Indications:

Applied in adults and children for radioisotopic examination of the kidneys and urinary tract:

- determination of effective renal blood flow (plasma flow);

- Investigation of total and separate secretory and excretory functions of the kidneys and urodynamics of the upper and lower urinary tract;

- assessment of anatomical features and topography of the kidneys;

- detection of violations of the kidney and urinary tract, determining the extent of these disorders in various diseases (renovascular hypertension,malignant formation of the bladder and prostate).

Contraindications:

Pregnancy, lactation, severe leukopenia.

Dosing and Administration:

The drug is administered intravenously with renography and determination of the clearance test, using 5.5-27.5 kBq / kg of body weight of the patient. Radiography is performed within 15-20 minutes after administration, information is recorded using four sensors located in the projection of the heart, both kidneys and the bladder.

To carry out dynamic renoscintigraphy, a drug with an activity of 0.55 MBq / kg of body weight of the patient (injected into a qubital vein) is used. The results are recorded in the "sitting" position with the back to the gamma camera detector.

If necessary, the drug can be diluted with 0.9% sodium chloride solution. All listed methods are performed in accordance with the methodological recommendations "Standardized methods of radioisotope diagnostics", Obninsk, 1987.

Radiation loads on the organs and tissues of the patient when using the drug "Sodium o-iodiphippurate.123 I "

Organs

Equivalent dose mGy / MBq

Bladder

0,01

Kidneys

0,005

Lower part of large intestine

0,005

Eggs

0,004

Ovaries

0,002

Uterus

0,005

Thyroid

0,003

The whole body (effective equivalent dose, mSv / MBq)

0,01
Side effects:

Side effects with the use of the drug for diagnostic purposes are not revealed.

Overdose:Overdose of the drug is unlikely in connection with the careful control of the injected activity in the conditions of a specialized hospital.
Interaction:In the doses used, interaction with other drugs was not noted.
Special instructions:

Work with the drug should be carried out in accordance with the "Basic Sanitary Rules for Ensuring Radiation Safety" (OSPORB-99), MU 2.6.1.1892-04

Form release / dosage:

Solution for intravenous administration.

Packaging:

They are supplied in hermetically ukuporennyh bottles with a capacity of 10 ml portions of 100, 300, 500, 1000 MBq for the set date and time of delivery.

A vial with a passport and instruction for medical use in a package transport packaging for radioactive substances.

Storage conditions:

The drug is stored in accordance with the "Basic Sanitary Rules for Ensuring Radiation Safety" (OSPORB-99), MU 2.6.1.1892-04.

Shelf life:

48 hours from the date and time of manufacture. Do not use after expiry date.

Terms of leave from pharmacies:For hospitals
Registration number:P N003739 / 01
Date of registration:10.12.2009
Expiration Date:Unlimited
The owner of the registration certificate:Radium Institute. VGKhlopina NGO, State Unitary Enterprise Radium Institute. VGKhlopina NGO, State Unitary Enterprise Russia
Manufacturer: & nbsp
Information update date: & nbsp24.05.2018
Illustrated instructions
    Instructions
    Up